Trinucleotide Repeat Expansion Disorders is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Trinucleotide repeat expansion disorders are a class of genetic diseases caused by the abnormal expansion of short tandem DNA repeats (typically 3-6 nucleotides) beyond a critical threshold length. Over fifty human disorders are caused by repeat expansions, including many of the most common neurodegenerative diseases such as [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, [spinocerebellar ataxias], [Friedreich's Ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia--TEMP--/diseases)--FIX--, [myotonic dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy--TEMP--/diseases)--FIX--, [fragile X-associated tremor/ataxia syndrome (FXTAS)[/diseases/[fragile-x-associated-tremor-ataxia-syndrome[/diseases/[fragile-x-associated-tremor-ataxia-syndrome[/diseases/[fragile-x-associated-tremor-ataxia-syndrome--TEMP--/diseases)--FIX--, and [dentatorubral-pallidoluysian atrophy (DRPLA)[/diseases/[drpla[/diseases/[drpla[/diseases/[drpla--TEMP--/diseases)--FIX-- (Paulson, 2018) [1].
These disorders share a common molecular etiology — the dynamic mutation of microsatellite repeats — but manifest through multiple distinct pathogenic mechanisms including protein
gain-of-function (e.g., polyglutamine toxicity), RNA-mediated toxicity, loss of gene function, and repeat-associated non-AUG (RAN) translation. Understanding these shared
mechanisms has opened cross-disease therapeutic strategies targeting the underlying repeat expansions [2].
The best-characterized class involves CAG repeat expansions within coding regions, producing proteins with extended polyglutamine tracts. These include:
- [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--: CAG expansion in the [HTT[/genes/[htt[/genes/[htt[/genes/[htt--TEMP--/genes)--FIX-- gene encoding [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- protein]; normal range 6-35 repeats, pathogenic >36 repeats (Bates et al., 2015)
- [Spinocerebellar ataxias] (SCA1, SCA2, SCA3/MJD, SCA6, SCA7, SCA17): CAG expansions in ataxin genes causing progressive cerebellar degeneration
- [Kennedy's disease (SBMA)[/diseases/[kennedys-disease[/diseases/[kennedys-disease[/diseases/[kennedys-disease--TEMP--/diseases)--FIX--: CAG expansion in the androgen receptor gene
- [DRPLA[/diseases/[dentatorubral-pallidoluysian-atrophy[/diseases/[dentatorubral-pallidoluysian-atrophy[/diseases/[dentatorubral-pallidoluysian-atrophy--TEMP--/diseases)--FIX--: CAG expansion in the atrophin-1 gene
Polyglutamine diseases share several features: dominant inheritance, progressive neurodegeneration with mid-life onset, inverse correlation between repeat length and age of onset (genetic anticipation), and formation of intranuclear protein inclusions (Lieberman et al., 2019) [3].
Repeat expansions in non-coding regions cause disease through fundamentally different mechanisms:
- [Friedreich's Ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia--TEMP--/diseases)--FIX--: GAA expansion in intron 1 of FXN, causing transcriptional silencing and loss of frataxin protein. This is the only common autosomal recessive repeat expansion disorder (Campuzano et al., 1996)
- [Myotonic dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy--TEMP--/diseases)--FIX-- type 1 (DM1): CTG expansion in the 3' UTR of DMPK; type 2 (DM2) involves CCTG expansion in CNBP
- [FXTAS[/diseases/[fxtas[/diseases/[fxtas[/diseases/[fxtas--TEMP--/diseases)--FIX--: CGG expansion (55-200 repeats) in the 5' UTR of FMR1
- [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX---ALS/FTD: GGGGCC hexanucleotide expansion in intron 1, the most common genetic cause of both [ALS[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX-- and [Frontotemporal Dementia (FTD)[/diseases/[ftd[/diseases/[ftd[/diseases/[ftd--TEMP--/diseases)--FIX-- (DeJesus-Hernandez et al., 2011)
The pathogenic mechanisms of repeat expansion disorders can be grouped into four major categories, often with multiple mechanisms operating simultaneously in a single disease (Malik et al., 2021):
In polyglutamine diseases, the expanded CAG repeat is translated into an abnormally long polyglutamine tract within the host protein. These expanded polyglutamine proteins undergo conformational changes, transitioning from soluble monomers to oligomeric intermediates and eventually to insoluble amyloid-like fibrils. This process shares features with [protein aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation[/mechanisms/[protein-aggregation--TEMP--/mechanisms)--FIX-- in other neurodegenerative diseases [4].
Key aspects of polyglutamine toxicity include:
- Misfolding and aggregation: Expanded polyglutamine tracts adopt β-sheet-rich conformations that self-assemble into amyloid fibrils, forming characteristic intranuclear inclusions (Scherzinger et al., 1999)
- Proteostatic stress: Aggregates overwhelm the [ubiquitin-proteasome system[/entities/[ubiquitin-proteasome-system[/entities/[ubiquitin-proteasome-system[/entities/[ubiquitin-proteasome-system--TEMP--/entities)--FIX-- and [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- machinery, impairing cellular [proteostasis]
- Transcriptional dysregulation: Expanded polyglutamine proteins sequester transcription factors (e.g., CBP, Sp1) and disrupt [histone modifications[/entities/[histone-modifications[/entities/[histone-modifications[/entities/[histone-modifications--TEMP--/entities)--FIX--, leading to widespread gene expression changes
- Mitochondrial dysfunction: PolyQ aggregates impair [mitochondrial dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics[/entities/[mitochondrial-dynamics--TEMP--/entities)--FIX-- and oxidative phosphorylation, increasing [reactive oxygen species[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- production (Johri & Beal, 2012)
- Prion-like spreading: Polyglutamine aggregates can template the misfolding of normal-length polyglutamine proteins and spread between cells in a [prion-like] manner
In non-coding repeat expansion disorders, the expanded repeat RNA itself is a primary toxic species. Transcribed repeat RNAs form complex secondary structures (hairpins, G-quadruplexes) that sequester essential RNA-binding proteins (RBPs), disrupting normal RNA processing (Wojciechowska & Krzyzosiak, 2011) [5].
RNA foci formation: Expanded repeat RNAs accumulate in nuclear foci, where they sequester specific RBPs:
- In DM1, expanded CUG repeats sequester muscleblind-like (MBNL) proteins, causing widespread splicing defects
- In [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX---ALS/FTD, GGGGCC repeat RNAs form G-quadruplex structures and sequester multiple RBPs including hnRNP H and nucleolin
- In FXTAS, CGG repeat RNAs sequester [FUS[/entities/[fus[/entities/[fus[/entities/[fus--TEMP--/entities)--FIX--, DROSHA/DGCR8, and other RBPs
Bidirectional transcription: Many repeat expansion loci are transcribed from both sense and antisense strands, doubling the potential for RNA-mediated toxicity. Antisense transcripts have been detected in [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX---ALS/FTD, SCA8, and DM1.
Some repeat expansions cause disease primarily through reduced expression of the affected gene:
- [Friedreich's Ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia--TEMP--/diseases)--FIX--: The GAA expansion in FXN induces heterochromatin formation and transcriptional silencing through R-loop formation and [DNA methylation[/entities/[dna-methylation[/entities/[dna-methylation[/entities/[dna-methylation--TEMP--/entities)--FIX--, reducing frataxin levels to 5-30% of normal. Frataxin is essential for mitochondrial iron-sulfur cluster assembly (Gottesfeld, 2019)
- Fragile X syndrome: CGG expansions >200 repeats cause hypermethylation and complete silencing of FMR1
- [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX---ALS/FTD: The GGGGCC expansion partially reduces [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX-- protein expression, although haploinsufficiency alone is insufficient to cause disease
RAN translation is a recently discovered mechanism in which expanded repeat sequences are translated without a canonical AUG start codon, producing toxic repeat polypeptides (Zu et al., 2011). RAN translation occurs in all three reading frames and from both sense and antisense strands, potentially generating six different homopolymeric or dipeptide-repeat proteins from a single expansion locus [6].
RAN translation in [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX---ALS/FTD: The GGGGCC expansion produces five distinct dipeptide repeat proteins (DPRs):
- Sense strand: poly(GA), poly(GP), poly(GR)
- Antisense strand: poly(PA), poly(PR), poly(GP)
The arginine-rich DPRs (poly-GR and poly-PR) are the most toxic, disrupting nucleocytoplasmic transport, ribosomal function, and [RNA metabolism[/mechanisms/[rna-metabolism[/mechanisms/[rna-metabolism[/mechanisms/[rna-metabolism--TEMP--/mechanisms)--FIX-- (Freibaum & Taylor, 2017). RAN translation is upregulated by cellular stress through phosphorylation of eIF2α, the core event of the integrated stress response, creating a feed-forward loop of toxicity (Green et al., 2017) [7].
RAN translation in other diseases: RAN translation has also been demonstrated in SCA8 (polyalanine, polyserine, polyglutamine from antisense transcript), DM1, FXTAS (FMRpolyG), and multiple polyglutamine diseases including [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- (Banez-Coronel et al., 2015).
¶ Genetic Anticipation and Repeat Instability
A hallmark of trinucleotide repeat disorders is genetic anticipation — the tendency for disease severity to increase and age of onset to decrease in successive generations. This occurs because expanded repeats are inherently unstable during DNA replication and repair, with a bias toward further expansion during intergenerational transmission [7].
Key factors influencing repeat instability include:
- Repeat length: Longer repeats are more unstable; a threshold length (typically 35-45 repeats for CAG disorders) marks the transition from stable to unstable alleles
- Parent of origin: In many disorders, paternal transmission is associated with larger expansions (e.g., [Huntington's Disease), while maternal transmission can cause larger expansions in others (e.g., DM1, where congenital forms require maternal transmission)
- DNA repair mechanisms: Mismatch repair proteins (MSH3, MSH2, PMS2) drive somatic expansion through a process involving oxidative damage and repair of repeat structures (Iyer et al., 2015)
- Somatic mosaicism: Repeat lengths vary between tissues and over time within an individual, with the [brain] and [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX-- often showing the greatest somatic expansion
The discovery that somatic expansion of repeats in post-mitotic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- drives disease progression has identified DNA mismatch repair (MMR) as a major therapeutic target. Genome-wide association studies (GWAS) in [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- identified variants in MSH3, PMS1, MLH1, and FAN1 as modifiers of disease onset, implicating the MMR pathway in somatic CAG expansion (GeM-HD Consortium, 2019) [8].
Several therapeutic strategies are being developed:
- MSH3 inhibition: Small molecules and antisense oligonucleotides targeting MSH3 to reduce somatic expansion
- [Antisense oligonucleotide (ASO) therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX--: Targeting repeat-containing transcripts for degradation (e.g., tominersen for Huntington's Disease, though Phase III results were mixed)
- Small interfering RNA (siRNA): Allele-selective silencing of expanded alleles
- CRISPR-based approaches: Excision of expanded repeats or modulation of repeat-associated chromatin
Despite the ubiquitous expression of most repeat expansion genes, each disease affects specific neuronal populations with remarkable selectivity — a pattern of [selective neuronal vulnerability[/mechanisms/[selective-neuronal-vulnerability[/mechanisms/[selective-neuronal-vulnerability[/mechanisms/[selective-neuronal-vulnerability--TEMP--/mechanisms)--FIX--:
- [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--: Medium spiny [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- of the [striatum[/brain-regions/[striatum[/brain-regions/[striatum[/brain-regions/[striatum--TEMP--/brain-regions)--FIX--
- SCAs: Purkinje cells of the [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX--
- [SBMA/Kennedy's disease]: Lower motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- of the [spinal cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord[/brain-regions/[spinal-cord--TEMP--/brain-regions)--FIX-- and [brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem[/brain-regions/[brainstem--TEMP--/brain-regions)--FIX--
- [Friedreich's Ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia--TEMP--/diseases)--FIX--: Dorsal root ganglia [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, dentate nucleus [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, and cardiomyocytes
- [C9orf72[/genes/[c9orf72[/genes/[c9orf72[/genes/[c9orf72--TEMP--/genes)--FIX---ALS/FTD: Motor [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- and frontal/temporal cortical [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--
This selective vulnerability likely reflects cell-type-specific differences in repeat instability rates, DNA repair capacity, transcriptional activity, and proteostatic burden (Bhatt et al., 2024) [9].
The shared molecular mechanisms across repeat expansion disorders have enabled cross-disease therapeutic approaches:
| Strategy |
Mechanism |
Target Diseases |
| ASO-mediated gene silencing |
Degradation of repeat-containing mRNA |
HD, C9-ALS/FTD, DM1, SCA |
| MSH3 inhibition |
Reduction of somatic repeat expansion |
HD, DM1, potentially all CAG disorders |
| Small molecule splicing correction |
Rescue of MBNL-dependent splicing |
DM1, DM2 |
| [Gene therapy[/treatments/[gene-therapy[/treatments/[gene-therapy[/treatments/[gene-therapy--TEMP--/treatments)--FIX-- (AAV-delivered) |
Gene replacement or silencing |
SCA, Friedreich's Ataxia |
| Integrated stress response modulation |
Reduction of RAN translation |
C9-ALS/FTD, FXTAS |
- [Antisense Oligonucleotide (ASO) Therapy in Neurodegeneration[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX--
The study of Trinucleotide Repeat Expansion Disorders has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Paulson, H. (2018]. Repeat expansion diseases. Handbook of Clinical Neurology, 147, 105-123. PMC6485936)
- [Malik, I., Kelley, C. P., Wang, E. T., & Todd, P. K. (2021]. Molecular mechanisms underlying nucleotide repeat expansion disorders. Nature Reviews Molecular Cell Biology, 22(9), 589-607. DOI
- [Bates, G. P., Dorsey, R., Gusella, J. F., et al. (2015]. Huntington's Disease. Nature Reviews Disease Primers, 1, 15005. DOI
- [Lieberman, A. P., Shakkottai, V. G., & Bhatt, N. P. (2019]. Polyglutamine repeats in neurodegenerative diseases. Annual Review of Pathology, 14, 1-27. DOI
- [DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., et al. (2011]. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. [Neuron[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, 72(2), 245-256. DOI
- [Campuzano, V., Montermini, L., Moltò, M. D., et al. (1996]. Friedreich's Ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science, 271(5254), 1423-1427. DOI
- [Wojciechowska, M., & Krzyzosiak, W. J. (2011]. Cellular toxicity of expanded RNA repeats: focus on RNA foci. Human Molecular Genetics, 20(19), 3811-3821. PMC5720136)
- [Gottesfeld, J. M. (2019]. Molecular mechanisms and therapeutics for the GAA·TTC expansion disease Friedreich ataxia. Neurotherapeutics, 16(4), 1032-1049. DOI
- [Zu, T., Gibbens, B., Doty, N. S., et al. (2011]. Non-ATG-initiated translation directed by microsatellite expansions. Proceedings of the National Academy of Sciences, 108(1), 260-265. DOI
- [Freibaum, B. D., & Taylor, J. P. (2017]. The role of dipeptide repeats in C9ORF72-related ALS-FTD. Frontiers in Molecular Neuroscience, 10, 35. PMC7930069)
- [Banez-Coronel, M., Ayhan, F., Taraez, A. D., et al. (2015]. RAN translation in Huntington's Disease. Neuron, 88(4), 667-677. DOI
- [Iyer, R. R., Pluciennik, A., Napierala, M., & Wells, R. D. (2015]. DNA triplet repeat expansion and mismatch repair. Annual Review of Biochemistry, 84, 199-226. DOI
- [Genetic Modifiers of Huntington's Disease (GeM-HD] Consortium. (2019). CAG repeat not polyglutamine length determines timing of Huntington's Disease onset. Cell, 178(4), 887-900. DOI
- [Bhatt, N., Bhatt, G., & Bhatt, N. (2024]. Selective vulnerability of [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- to repeat expansion disorders. Trends in Neurosciences, 47(1), 60-72. DOI
- [Johri, A., & Beal, M. F. (2012]. Mitochondrial dysfunction in neurodegenerative diseases. Journal of Pharmacology and Experimental Therapeutics, 342(3), 619-630. DOI
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
33% |
| Effect Sizes |
50% |
| Contradicting Evidence |
33% |
| Mechanistic Completeness |
50% |
Overall Confidence: 51%